SCHEMBL413223

SCHEMBL413223

NC(=O)C1(N)CC1

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Hydrochloric Acid SCHEMBL4765076 0.97
SCHEMBL1911324 0.87
SCHEMBL3714826 0.87
SCHEMBL18614579 0.86 NSD2 (0.33)
Hydrochloric Acid SCHEMBL1920271 0.84 TSHR (0.35)
Hydrochloric Acid SCHEMBL14955726 0.84
SCHEMBL14813765 0.84 TSHR (0.40)
SCHEMBL353640 0.84 TSHR (0.40)
Hydrochloric Acid SCHEMBL4600581 0.82 TSHR (0.39)
SCHEMBL4606683 0.80 KDM4E (0.33)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 212 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8658570-B2 Use of anthranilamide derivatives for controlling insects and spider mites by drenching, soil mixing, furrow treatment, drip application, soil, stem or flower injection, in hydroponic systems, by planting hole treatment or dip application, floating or seedbox application or by treating seed, and also for enhancing the stress tolerance of plants to abiotic stress BAYER CROPSCIENCE AG (DE) 2014-02-25 US claimed
EP-4680609-A1 KRAS MODULATORS AND USES THEREOF Quanta Therapeutics, Inc. (US) 2026-01-21 EP disclosed
US-20260008789-A1 KRAS MODULATORS AND USES THEREOF QUANTA THERAPEUTICS INC (US) 2026-01-08 US disclosed
US-20250340516-A1 Isoquinolinones as Modulators of POLRMT PRETZEL THERAPEUTICS, INC. (US) 2025-11-06 US disclosed
US-20250320224-A1 NOVEL PAR-2 INHIBITORS DOMAIN THERAPEUTICS (FR) 2025-10-16 US disclosed
US-12421254-B2 KRAS modulators and uses thereof QUANTA THERAPEUTICS, INC. (US) 2025-09-23 US disclosed
EP-4568948-A1 COMPOUNDS FOR TREATING CANCER Genesis Therapeutics, Inc. (US) 2025-06-18 EP disclosed
EP-4532496-A1 NOVEL PAR-2 INHIBITORS Domain Therapeutics (FR) 2025-04-09 EP disclosed
US-20250051365-A1 KRAS MODULATORS AND USES THEREOF QUANTA THERAPEUTICS, INC. 2025-02-13 US disclosed
CN-119384420-A Novel PAR-2 inhibitors 多曼治疗学公司 2025-01-28 CN disclosed
WO-2005051895-A1 ORGANIC COMPOUNDS NOVARTIS AG (CH) 2005-06-09 WO disclosed
EP-1510516-A1 PYRAZOLE COMPOUND AND MEDICINAL COMPOSITION CONTAINING THE SAME Eisai Co., Ltd. (JP) 2005-03-02 EP disclosed
WO-2005016886-A1 SULFONYL SUBSTITUTED N-(BIARYLMETHYL) AMINOCYCLOPROPANECARBOXAMIDES MERCK & CO., INC. (US) 2005-02-24 WO disclosed
US-6649642-B2 Useful in the treatment of autoimmune and other cathepsin related diseases. BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. 2003-11-18 US disclosed
US-20030087939-A1 NOVEL SUCCINATE DERIVATIVE COMPOUNDS USEFUL AS CYSTEINE PROTEASE INHIBITORS BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) 2003-05-08 US disclosed
EP-1204652-A1 NOVEL SUCCINATE DERIVATIVE COMPOUNDS USEFUL AS CYSTEINE PROTEASE INHIBITORS BOEHRINGER INGELHEIM PHARMACEUTICALS INC. (US) 2002-05-15 EP disclosed
US-20010041700-A1 Novel succinate derivative compounds useful as cysteine protease inhibitors BEKKALI YOUNES (US) 2001-11-15 US disclosed
US-6313117-B1 TREATING AUTOIMMUNE DISORDERS BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. 2001-11-06 US disclosed
WO-2001009110-A1 NOVEL SUCCINATE DERIVATIVE COMPOUNDS USEFUL AS CYSTEINE PROTEASE INHIBITORS BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) 2001-02-08 WO disclosed
US-4478836-A 1-Aryl 2-aminomethyl cyclopropane carboxyamide (Z) derivatives and their use as useful drugs in the treatment of disturbances of the central nervous system PIERRE FABRE S.A. (FR) 1984-10-23 US disclosed